Literature DB >> 26440889

Reversion of FMR1 Methylation and Silencing by Editing the Triplet Repeats in Fragile X iPSC-Derived Neurons.

Chul-Yong Park1, Tomer Halevy2, Dongjin R Lee1, Jin Jea Sung1, Jae Souk Lee1, Ofra Yanuka2, Nissim Benvenisty3, Dong-Wook Kim4.   

Abstract

Fragile X syndrome (FXS) is the most common form of inherited intellectual disability, resulting from a CGG repeat expansion in the fragile X mental retardation 1 (FMR1) gene. Here, we report a strategy for CGG repeat correction using CRISPR/Cas9 for targeted deletion in both embryonic stem cells and induced pluripotent stem cells derived from FXS patients. Following gene correction in FXS induced pluripotent stem cells, FMR1 expression was restored and sustained in neural precursor cells and mature neurons. Strikingly, after removal of the CGG repeats, the upstream CpG island of the FMR1 promoter showed extensive demethylation, an open chromatin state, and transcription initiation. These results suggest a silencing maintenance mechanism for the FMR1 promoter that is dependent on the existence of the CGG repeat expansion. Our strategy for deletion of trinucleotide repeats provides further insights into the molecular mechanisms of FXS and future therapies of trinucleotide repeat disorders.
Copyright © 2015 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26440889     DOI: 10.1016/j.celrep.2015.08.084

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  66 in total

Review 1.  Gene-targeting pharmaceuticals for single-gene disorders.

Authors:  Arthur L Beaudet; Linyan Meng
Journal:  Hum Mol Genet       Date:  2015-11-30       Impact factor: 6.150

2.  Chemically Modified Cpf1-CRISPR RNAs Mediate Efficient Genome Editing in Mammalian Cells.

Authors:  Moira A McMahon; Thazha P Prakash; Don W Cleveland; C Frank Bennett; Meghdad Rahdar
Journal:  Mol Ther       Date:  2018-03-06       Impact factor: 11.454

Review 3.  Molecular Pathophysiology of Fragile X-Associated Tremor/Ataxia Syndrome and Perspectives for Drug Development.

Authors:  Teresa Botta-Orfila; Gian Gaetano Tartaglia; Aubin Michalon
Journal:  Cerebellum       Date:  2016-10       Impact factor: 3.847

4.  Gene therapy: Gene-editing therapy for neurological disease.

Authors:  Moira A McMahon; Don W Cleveland
Journal:  Nat Rev Neurol       Date:  2016-12-16       Impact factor: 42.937

5.  Predicting the mutations generated by repair of Cas9-induced double-strand breaks.

Authors:  Felicity Allen; Luca Crepaldi; Clara Alsinet; Alexander J Strong; Vitalii Kleshchevnikov; Pietro De Angeli; Petra Páleníková; Anton Khodak; Vladimir Kiselev; Michael Kosicki; Andrew R Bassett; Heather Harding; Yaron Galanty; Francisco Muñoz-Martínez; Emmanouil Metzakopian; Stephen P Jackson; Leopold Parts
Journal:  Nat Biotechnol       Date:  2018-11-27       Impact factor: 54.908

6.  Nanoparticle delivery of CRISPR into the brain rescues a mouse model of fragile X syndrome from exaggerated repetitive behaviours.

Authors:  Bumwhee Lee; Kunwoo Lee; Shree Panda; Rodrigo Gonzales-Rojas; Anthony Chong; Vladislav Bugay; Hyo Min Park; Robert Brenner; Niren Murthy; Hye Young Lee
Journal:  Nat Biomed Eng       Date:  2018-06-25       Impact factor: 25.671

7.  The fragile X mutation impairs homeostatic plasticity in human neurons by blocking synaptic retinoic acid signaling.

Authors:  Zhenjie Zhang; Samuele G Marro; Yingsha Zhang; Kristin L Arendt; Christopher Patzke; Bo Zhou; Tyler Fair; Nan Yang; Thomas C Südhof; Marius Wernig; Lu Chen
Journal:  Sci Transl Med       Date:  2018-08-01       Impact factor: 17.956

8.  In Vivo Single-Cell Genotyping of Mouse Cortical Neurons Transfected with CRISPR/Cas9.

Authors:  André Steinecke; Nobuhiro Kurabayashi; Yasufumi Hayano; Yugo Ishino; Hiroki Taniguchi
Journal:  Cell Rep       Date:  2019-07-09       Impact factor: 9.423

Review 9.  Modeling simple repeat expansion diseases with iPSC technology.

Authors:  Edyta Jaworska; Emilia Kozlowska; Pawel M Switonski; Wlodzimierz J Krzyzosiak
Journal:  Cell Mol Life Sci       Date:  2016-06-03       Impact factor: 9.261

Review 10.  Genome Editing in Induced Pluripotent Stem Cells using CRISPR/Cas9.

Authors:  Ronen Ben Jehuda; Yuval Shemer; Ofer Binah
Journal:  Stem Cell Rev Rep       Date:  2018-06       Impact factor: 5.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.